Form 4: Amphastar Pharmaceuticals Executive Rong Zhou Reports Acquisition of Stock Options and Restricted Stock Units

Senior EVP Rong Zhou reports acquisition of stock options and restricted stock units in Amphastar Pharmaceuticals.

Summary

• On March 4, 2024, Rong Zhou, Senior EVP of Production Center at Amphastar Pharmaceuticals, reported the acquisition of 12,521 shares of common stock in the form of restricted stock units (RSUs) and 26,378 employee stock options.
• The RSUs vest in four equal annual installments beginning on March 4, 2025.
• The stock options, with an exercise price of $46.68, also vest in four equal annual installments beginning on March 4, 2025.
• Following the reported transactions, Zhou directly owns 124,941 shares of common stock.
• Zhou also has indirect ownership of 99,668 shares held by the Zhou Family Trust, for which Zhou serves as a trustee, and 5,000 shares held by Zhou's spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of stock options and RSUs by a senior executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment by the executive to the company's success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the executive's alignment with the company's long-term performance.

Key Dates